FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655006> ?p ?o ?g. }

• W4385655006 endingPage "e80756cf" @default.
• W4385655006 startingPage "e80756cf" @default.
• W4385655006 abstract "Topic: 16. Myeloproliferative neoplasms - Clinical Background: Atrial fibrillation (AF) is the most common arrythmia (1-2% of the general population) and is associated with high risk of arterial thrombotic events. AF is not well characterized in the context of myeloproliferative neoplasms (MPN). Recent studies imply that thrombotic risk stratification among MPN AF patients may be suboptimal using the standard CHA2DS2VASC score, and true predictor of thrombotic risk may be presence of myelofibrosis instead. Clinical context in which AF occurs in myelofibrosis patients had not been investigated so far, but such analysis is needed to better understand why is the presence of myelofibrosis in particular the main predictor of thrombotic events among AF MPN patients. Aims: To evaluate prevalence and clinical associations of AF among patients with myelofibrosis. Methods: We retrospectively investigated a cohort of 154 patients with overt myelofibrosis treated in 6 Croatian hematology centers in period 2004-2022. Diagnoses were reassessed according to the 2016 WHO criteria for primary myelofibrosis (PMF) and the 2008 IWGMRT criteria for secondary myelofibrosis (SMF). Presence of AF documented in medical records and clinical correlations of AF status with main disease related characteristics were analyzed. Results: Among a total of 154 patients, 86 had PMF, 35 had post polycythemia vera (PV) and 33 had post essential thrombocythemia (ET) SMF. Median age was 69 years. There were 91 (59%) males, 111 (75%) patients were JAK2, 9 (7.3%) CALR and 4 (3.3%) MPL mutated. AF was present in 15 (9.7%) patients with myelofibrosis. There were no significant associations of AF with neither etiology of myelofibrosis, age, sex, mutational status, degree of bone marrow fibrosis, spleen size, history of thrombosis, estimated glomerular filtration rate, hemoglobin, WBC nor platelet count (P>0.05 for all analyses). DIPSS score did not differ between AF and non-AF PMF patients, but MYSEC-PM score was significantly higher among AF SMF patients (P=0.029). AF in comparison to non-AF patients more frequently had constitutional symptoms (87% vs 54%, P=0.015), positive bleeding history (27% vs 6%, P=0.004), heart failure (47% vs 12%, P<0.001), obesity (21% vs 4%, P=0.010), lower MCHC (313 vs 318 g/L, P=0.031), higher urea (median 8.5 vs 6.8 g/L, P=0.009) and higher CHA2DS2VASC score (4 vs 3 points, P=0.003). AF more frequently received anticoagulants and diuretics than non-AF patients (P<0.05), whereas similar rates of cytoreductive therapy and aspirin were utilized. Despite all myelofibrosis patients with AF patients having CHA2DS2VASC score ≥2 points, only 60% of them received anticoagulant therapy, 27% received aspirin and 73% received cytoreductive therapy. No significant difference in survival and thrombosis was observed between AF and non-AF myelofibrosis patients (P>0.05 for all analyses). Summary/Conclusion: AF is frequent in patients with myelofibrosis and might be associated with higher frequency of constitutional symptoms, particular cardiovascular comorbidities and consistently high predetermined CHAD2DS2VASC risk. Nevertheless, unexpectedly low proportion of patients receives anticoagulant therapy, possibly due to anticipated risk of bleeding and cytopenias common in myelofibrosis patients. Despite these differences, similar thrombosis and survival rates were observed between AF and non-AF patients. It remains a question whether suboptimal treatment or presence myelofibrosis itself might be a risk factor for unfavorable outcomes among AF MPN patients. Keywords: Arterial thrombosis, Myeloproliferative disorder, Myelofibrosis" @default.
• W4385655006 created "2023-08-09" @default.
• W4385655006 creator A5002697524 @default.
• W4385655006 creator A5011170839 @default.
• W4385655006 creator A5015207045 @default.
• W4385655006 creator A5017531937 @default.
• W4385655006 creator A5034027419 @default.
• W4385655006 creator A5044915309 @default.
• W4385655006 creator A5049940470 @default.
• W4385655006 creator A5078947304 @default.
• W4385655006 creator A5079649873 @default.
• W4385655006 creator A5085755441 @default.
• W4385655006 date "2023-08-01" @default.
• W4385655006 modified "2023-09-27" @default.
• W4385655006 title "PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED" @default.
• W4385655006 doi "https://doi.org/10.1097/01.hs9.0000975624.80756.cf" @default.
• W4385655006 hasPublicationYear "2023" @default.
• W4385655006 type Work @default.
• W4385655006 citedByCount "0" @default.
• W4385655006 crossrefType "journal-article" @default.
• W4385655006 hasAuthorship W4385655006A5002697524 @default.
• W4385655006 hasAuthorship W4385655006A5011170839 @default.
• W4385655006 hasAuthorship W4385655006A5015207045 @default.
• W4385655006 hasAuthorship W4385655006A5017531937 @default.
• W4385655006 hasAuthorship W4385655006A5034027419 @default.
• W4385655006 hasAuthorship W4385655006A5044915309 @default.
• W4385655006 hasAuthorship W4385655006A5049940470 @default.
• W4385655006 hasAuthorship W4385655006A5078947304 @default.
• W4385655006 hasAuthorship W4385655006A5079649873 @default.
• W4385655006 hasAuthorship W4385655006A5085755441 @default.
• W4385655006 hasBestOaLocation W43856550061 @default.
• W4385655006 hasConcept C126322002 @default.
• W4385655006 hasConcept C151730666 @default.
• W4385655006 hasConcept C201903717 @default.
• W4385655006 hasConcept C2778837598 @default.
• W4385655006 hasConcept C2779161974 @default.
• W4385655006 hasConcept C2779343474 @default.
• W4385655006 hasConcept C2780007613 @default.
• W4385655006 hasConcept C2780076729 @default.
• W4385655006 hasConcept C2781057849 @default.
• W4385655006 hasConcept C2908647359 @default.
• W4385655006 hasConcept C71924100 @default.
• W4385655006 hasConcept C72563966 @default.
• W4385655006 hasConcept C86803240 @default.
• W4385655006 hasConcept C90924648 @default.
• W4385655006 hasConcept C99454951 @default.
• W4385655006 hasConceptScore W4385655006C126322002 @default.
• W4385655006 hasConceptScore W4385655006C151730666 @default.
• W4385655006 hasConceptScore W4385655006C201903717 @default.
• W4385655006 hasConceptScore W4385655006C2778837598 @default.
• W4385655006 hasConceptScore W4385655006C2779161974 @default.
• W4385655006 hasConceptScore W4385655006C2779343474 @default.
• W4385655006 hasConceptScore W4385655006C2780007613 @default.
• W4385655006 hasConceptScore W4385655006C2780076729 @default.
• W4385655006 hasConceptScore W4385655006C2781057849 @default.
• W4385655006 hasConceptScore W4385655006C2908647359 @default.
• W4385655006 hasConceptScore W4385655006C71924100 @default.
• W4385655006 hasConceptScore W4385655006C72563966 @default.
• W4385655006 hasConceptScore W4385655006C86803240 @default.
• W4385655006 hasConceptScore W4385655006C90924648 @default.
• W4385655006 hasConceptScore W4385655006C99454951 @default.
• W4385655006 hasIssue "S3" @default.
• W4385655006 hasLocation W43856550061 @default.
• W4385655006 hasLocation W43856550062 @default.
• W4385655006 hasOpenAccess W4385655006 @default.
• W4385655006 hasPrimaryLocation W43856550061 @default.
• W4385655006 hasRelatedWork W2012828222 @default.
• W4385655006 hasRelatedWork W2098715171 @default.
• W4385655006 hasRelatedWork W2150058579 @default.
• W4385655006 hasRelatedWork W2203054457 @default.
• W4385655006 hasRelatedWork W2279744777 @default.
• W4385655006 hasRelatedWork W2762863431 @default.
• W4385655006 hasRelatedWork W3015241011 @default.
• W4385655006 hasRelatedWork W3032977845 @default.
• W4385655006 hasRelatedWork W4283271588 @default.
• W4385655006 hasRelatedWork W91111500 @default.
• W4385655006 hasVolume "7" @default.
• W4385655006 isParatext "false" @default.
• W4385655006 isRetracted "false" @default.
• W4385655006 workType "article" @default.